Backhaus

Philogen Reports Full Year 2021 Results and Provides Corporate Update

Retrieved on: 
Friday, April 1, 2022
Chemical library, European Journal of Nuclear Medicine and Molecular Imaging, Disease, Blood, EDA, Glioblastoma, Cash Cash, Therapy, Ligand, Group, L19, Interleukin, ORR, Nuclear medicine, Initial public offering, Mouse, EDB, MGMT, Survival, Research, Glioma, Lomustine, Observation, Antigen, Neoplasm, IL12, Cancer, Tissue, TNF, European Journal, Inflammation, Google Images, Intellectual property, CRO, Molecular imaging, News, IL2, BST, Soft-tissue sarcoma, IPO, IL10, Patient, Partnership, Backhaus, Pharmaceutical industry, Medical imaging, Fine chemical, Cryptocurrency, Vaccine, Jaden Philogene-Bidace, Pfizer, Fibronectin, Phase

In 2022 Philogen will limit cash burn (or possibly have no cash burn), due to existing and new partnerships, despite increased spending for clinical trials.

Key Points: 
  • In 2022 Philogen will limit cash burn (or possibly have no cash burn), due to existing and new partnerships, despite increased spending for clinical trials.
  • Siena (Italy), 1 April 2022 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics, provides an update regarding the Companys full year 2021 results and recent corporate developments.
  • "We are excited for the great progress we have made following our listing on the Italian Stock Exchange in March 2021.
  • Philogen has a rich pipeline of late-stage clinical assets and continues to innovate by generating new prototypes, commented Prof. Dr. Dario Neri, Chief Executive Officer of Philogen.

Aidéo Technologies Expands Executive Team with Two Key New Hires

Retrieved on: 
Wednesday, January 19, 2022
People, Technology, IOT, Harvard University, Digi, Health, Mentorship, PALM, PAC, Backhaus, Revenue cycle management, RCM, CEO, GLOBE, Solution, Massachusetts Institute of Technology, Chief analytics officer, Information technology, Silicon, Artificial intelligence, Doctor of Philosophy, Data science, Engineering, Advanced Technology Program, Gemini, Machine learning, Management

Sroka will lead the companys expanding data sciences team and will help lead the companys expansion of its capabilities in artificial intelligence and machine learning.

Key Points: 
  • Sroka will lead the companys expanding data sciences team and will help lead the companys expansion of its capabilities in artificial intelligence and machine learning.
  • The vision and opportunity to scale at Aido Technologies captured my attention from the very beginning, Backhaus said.
  • Aido Technologies provides software automation tools using artificial intelligence and machine learning to the healthcare industry.
  • Established in 2009, Aido Technologies has development centers in West Palm Beach, Fla., Silicon Valley and Mumbai, India.